UK regulator approves Alzheimer’s drug, but government unlikely to cover costs

Q: How long will it take to read this news story?

The story "UK regulator approves Alzheimer’s drug, but government unlikely to cover costs" has 607 words across 22 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "UK regulator approves Alzheimer’s drug, but government unlikely to cover costs" was covered 2 days ago by Business Mirror, a news publisher based in Philippines.

Q: How trustworthy is 'Business Mirror' news outlet?

Business Mirror is a fully independent (privately-owned) news outlet established in 2005 that covers mostly business and startups news. The outlet is headquartered in Philippines and publishes an average of 2 news stories per day. It's most recent story was published 18 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22309636</li><li>URL: https://beamstart.com/news/uk-regulator-approves-alzheimers-drug-172504755268</li></ul>

Business Mirror Logo Business Mirror 2d ago

UK regulator approves Alzheimer’s drug, but government unlikely to cover costs - Business Mirror

Quick Summary:

But the UK government likely won’t be paying for it after an independent agency separately issued draft guidance concluding that the benefits of Leqembi “cannot be considered good value for the taxpayer.

In addition to the cost of the drug, providing Leqembi requires that patients be hospitalized every two weeks to receive it and be closely monitored for side effects.

Experts also noted the lack of data regarding the long-term effectiveness of Leqembi, made by Japanese drugmaker Eisai.“The reality is that the benefits this first treatment provides are just too small to justify the significant cost,” said Dr.